1. Home
  2. Live Updates
  3. Michel janicot

Michel Janicot News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michel janicot. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michel Janicot Today - Breaking & Trending Today

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

BioPharma ....

United States , Basel Stadt , Lisa Meier Mcshane , Paula Okeefe , Rob Manguso , Marcela Maus , Michel Janicot , Anne Rios , Katrin Rupalla , Professor At Harvard Medical School , National Cancer Institute , Division Of Cancer Treatment , Meeting Of The Association For Cancer Immunotherapy , German Cancer Research Center , Harvard Medical School , Cancer Center , Princess Maxima Center , Broad Institute , Hospital Cancer Center , Us National Institutes Of Health , Cancer Program , Annual Meeting , Associate Director , Cancer Treatment , Associate Professor , Paulao Keefe Chair ,

Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer

BioPharma ....

Basel Stadt , France General , Rhone Poulenc Rorer , Katrin Rupalla , Jmi Onconsulting , Michel Janicot , University Of Paris , Chief Development Officer , Ymmunobio Founder , Managing Director ,

Ymmunobio to Present Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

BioPharma ....

United States , Basel Stadt , Katrin Rupalla , Michel Janicot , Alexej Schmidt , Iris Helfrich , University Of Umea , Society For Immunotherapy Of Cancer , University Essen Duisburg , University Of Munich ,

Synthetic microRNA can serve as a novel therapeutic agent for treating human cancer

Oncotarget published "Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology" which reported that the authors comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic ....

Michel Janicot , Emily Henderson , Oncotarget Research Output , Janicot Research Team , Cell Cycle , Cell Proliferation , Dna Damage , Ene Expression , N Vivo , எமிலி ஹென்டர்சன் ,

Oncotarget: 1B3 supports strong potential for therapeutic intervention in oncology


Interestingly, the exact mechanism through which 1B3 reduced cell proliferation varied between cell lines.
1B3 efficiently reduced target gene expression, leading to reduced cell proliferation/survival, cell cycle arrest, induction of apoptosis, increased cell senescence, DNA damage, and inhibition of migration.
SiRNA silencing of 1B3 target mRNAs further highlighted the advantage of the pleiotropic mechanism of 1B3 action, as repression of individual targets did not achieve the same robust effect on cell proliferation in all cell lines.
Together, these data strongly support the development of 1B3 as a novel therapeutic agent for treatment of human cancer.
Dr. Michel Janicot from InteRNA Technologies BV said, ....

Michel Janicot , Janicot Research Team , Impact Journals , Oncotargetresearch Output , Medicine Health , Breast Cancer , Prostate Cancer , ஒலி கிளவுட் , தாக்கம் பத்திரிகைகள் , மருந்து ஆரோக்கியம் ,